iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
4 enrolled
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
36 enrolled 17 charts
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Phase 2 Terminated
17 enrolled
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Phase 1 Terminated
1 enrolled
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Phase 2 Terminated
45 enrolled
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase 1/2 Terminated
32 enrolled 18 charts
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Phase 1 Terminated
18 enrolled
Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Phase 1 Terminated
10 enrolled
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 5 charts
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Phase 1/2 Terminated
58 enrolled
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase 2 Terminated
1 enrolled 1 chart
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
Phase 3 Terminated
269 enrolled 9 charts
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase 1/2 Terminated
46 enrolled 29 charts
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Phase 2 Terminated
10 enrolled 37 charts
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Terminated
12 enrolled
DMV
Phase 1/2 Terminated
13 enrolled 8 charts
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Phase 1/2 Terminated
83 enrolled 31 charts
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Phase 1/2 Terminated
6 enrolled 8 charts
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Phase 1/2 Terminated
7 enrolled 9 charts
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
11 enrolled 9 charts
Velcadito
Phase 4 Terminated
24 enrolled
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Phase 2 Terminated
4 enrolled 6 charts
TAVAB
Phase 2 Terminated
11 enrolled
Trial of Romidepsin and Bortezomib for Multiple Myeloma
Phase 2 Terminated
32 enrolled 14 charts
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Terminated
9 enrolled 2 charts
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Phase 2 Terminated
2 enrolled 11 charts
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Phase 1 Terminated
20 enrolled
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
32 enrolled 12 charts
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 2 Terminated
3 enrolled 6 charts
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Phase 2 Terminated
24 enrolled 24 charts
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Phase 3 Terminated
147 enrolled
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Phase 1/2 Terminated
22 enrolled 21 charts
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
7 enrolled
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Phase 2 Terminated
23 enrolled 9 charts
VRCD
Phase 2 Terminated
12 enrolled 7 charts
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
Phase 1/2 Terminated
19 enrolled 10 charts
VelRand
Phase 3 Terminated
3 enrolled 11 charts
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 6 charts
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase 2 Terminated
27 enrolled
PANORAMA4
Phase 2 Terminated
6 enrolled 7 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Phase 2 Terminated
12 enrolled 10 charts
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Phase 3 Terminated
135 enrolled
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase 2 Terminated
24 enrolled 3 charts
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
32 enrolled
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Terminated
16 enrolled 7 charts
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Phase 2 Terminated
7 enrolled 8 charts